SCHEMBL6636085

SCHEMBL6636085

Fc1ccc2c(C3CCC4(CC3)OCCO4)c[nH]c2c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.53
DRD2 P14416 4/20 0.53
ADRA1D P25100 3/20 0.51
IDO1 P14902 1/20 0.48
HTR2A P28223 5/20 0.47
OPRM1 P35372 1/20 0.46
OPRL1 P41146 1/20 0.46
HTR1A P08908 3/20 0.45
ADRA1B P35368 1/20 0.44
HTR1B P28222 2/20 0.42
HTR1D P28221 1/20 0.42
APP P05067 2/20 0.42
HTR7 P34969 2/20 0.41
KCNH2 Q12809 2/20 0.41
DRD1 P21728 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6636225 0.90 SLC6A4 (0.52) SLC6A4IDO1HTR2AOPRM1OPRL1
SCHEMBL4354945 0.83 SLC6A4 (0.61) SLC6A4DRD2ADRA1DIDO1HTR2A
SCHEMBL6635816 0.81 HTR2C (0.59) ADRA1DHTR2A
SCHEMBL2904310 0.77 HTR2A (0.64) SLC6A4DRD2ADRA1DIDO1HTR2A
SCHEMBL30275187 0.77 HTR2A (0.64) SLC6A4DRD2ADRA1DIDO1HTR2A
SCHEMBL6636989 0.76 SLC6A4 (0.52) SLC6A4IDO1OPRM1OPRL1HTR1A
SCHEMBL6637981 0.76 SLC6A4 (0.52) SLC6A4IDO1HTR2AOPRM1OPRL1
SCHEMBL19972565 0.76 HSD11B1 (0.45) HTR2AHTR1AHTR1DAPP
Hydrochloric Acid SCHEMBL6248133 0.76 HTR2C (0.63) SLC6A4DRD2ADRA1DIDO1HTR2A
SCHEMBL4671007 0.76 SLC6A4 (0.59) SLC6A4DRD2ADRA1DIDO1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147083-B1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION WYETH CORP (US) 2004-06-16 EP disclosed
US-6465482-B2 ANTIDEPRESSANTS; ANXIOLYTIC AGENTS; SEROTONIN-AFFECTED NERVOUS SYSTEM DISORDERS; ACTING AT THE 5-HT1A AUTORECEPTORS CONCOMMITANTLY WITH 5-HT TRANSPORTERS; ANTISEROTONIN AGENTS; SEROTONIN REUPTAKE INHIBITORS; HT3 RECEPTOR ANTAGONISTS WYETH 2002-10-15 US disclosed
US-20020045628-A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression AMERICAN HOME PRODUCTS CORPORATION (US) 2002-04-18 US disclosed
US-6337326-B1 CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS AMERICAN HOME PRODUCTS CORPORATION 2002-01-08 US disclosed
US-6313126-B1 FOR THRERAPY OF DISORDERS ASSOCIATED WITH DYSFUNCTION IN SEROTONERGIC NEUROTRANSMISSION, INCLUDING DEPRESSION AND ANXIETY AMERICAN HOME PRODUCTS CORP 2001-11-06 US disclosed
EP-1147083-A1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 2001-10-24 EP disclosed
WO-2000040554-A1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 2000-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045628-A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression HTR2C, TPH1, TPH2 SLC6A4 43/4885DRD2 27/4885ADRA1D 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.